Use of metformin in polycystic ovary syndrome

Ruchi Mathur, Carolyn J. Alexander, Jacqueline Yano, Bradley Trivax, Ricardo Azziz

Research output: Contribution to journalReview article

82 Citations (Scopus)

Abstract

Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.

Original languageEnglish (US)
Pages (from-to)596-609
Number of pages14
JournalAmerican Journal of Obstetrics and Gynecology
Volume199
Issue number6
DOIs
StatePublished - Dec 1 2008

Fingerprint

Polycystic Ovary Syndrome
Metformin
Ovulation Induction
Type 2 Diabetes Mellitus
Pregnancy Tests
Clomiphene
Hyperinsulinism
Therapeutics
Pregnancy Outcome
Glucose Tolerance Test
Dyslipidemias
Guidelines
Insulin
Inflammation
Pregnancy
Population

Keywords

  • infertility
  • insulin resistance
  • metformin
  • polycystic ovary syndrome
  • pregnancy

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008). Use of metformin in polycystic ovary syndrome. American Journal of Obstetrics and Gynecology, 199(6), 596-609. https://doi.org/10.1016/j.ajog.2008.09.010

Use of metformin in polycystic ovary syndrome. / Mathur, Ruchi; Alexander, Carolyn J.; Yano, Jacqueline; Trivax, Bradley; Azziz, Ricardo.

In: American Journal of Obstetrics and Gynecology, Vol. 199, No. 6, 01.12.2008, p. 596-609.

Research output: Contribution to journalReview article

Mathur, R, Alexander, CJ, Yano, J, Trivax, B & Azziz, R 2008, 'Use of metformin in polycystic ovary syndrome', American Journal of Obstetrics and Gynecology, vol. 199, no. 6, pp. 596-609. https://doi.org/10.1016/j.ajog.2008.09.010
Mathur, Ruchi ; Alexander, Carolyn J. ; Yano, Jacqueline ; Trivax, Bradley ; Azziz, Ricardo. / Use of metformin in polycystic ovary syndrome. In: American Journal of Obstetrics and Gynecology. 2008 ; Vol. 199, No. 6. pp. 596-609.
@article{aed9998479b044e6b6b7507c4eec6840,
title = "Use of metformin in polycystic ovary syndrome",
abstract = "Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.",
keywords = "infertility, insulin resistance, metformin, polycystic ovary syndrome, pregnancy",
author = "Ruchi Mathur and Alexander, {Carolyn J.} and Jacqueline Yano and Bradley Trivax and Ricardo Azziz",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.ajog.2008.09.010",
language = "English (US)",
volume = "199",
pages = "596--609",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Use of metformin in polycystic ovary syndrome

AU - Mathur, Ruchi

AU - Alexander, Carolyn J.

AU - Yano, Jacqueline

AU - Trivax, Bradley

AU - Azziz, Ricardo

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.

AB - Women with polycystic ovary syndrome (PCOS) have a myriad of phenotypic and clinical features that may guide therapeutic options for metabolic protection and ovulation induction. The use of metformin may prove beneficial in a subset of the population of women with PCOS. Hyperinsulinemia, as demonstrated by elevated insulin levels on a 2-hour 75-g load glucose tolerance test, is an important parameter in deciding whether or not to initiate metformin therapy to women with PCOS with the hope of preventing or delaying the onset of type 2 diabetes mellitus (DM). Cardiovascular risk factors including markers of subclinical inflammation, and dyslipidemia may also be improved by metformin therapy. For ovulation induction, metformin is not as effective as clomiphene citrate as first-line therapy for women with PCOS. There are no clear data to suggest that metformin reduces pregnancy loss or improves pregnancy outcome in PCOS, and it is currently recommended that metformin be discontinued with the first positive pregnancy test result, unless there are other medical indications (eg, type 2 DM). This review addresses practical management guidelines for the uses of metformin in women with PCOS.

KW - infertility

KW - insulin resistance

KW - metformin

KW - polycystic ovary syndrome

KW - pregnancy

UR - http://www.scopus.com/inward/record.url?scp=57149142767&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149142767&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2008.09.010

DO - 10.1016/j.ajog.2008.09.010

M3 - Review article

C2 - 19084097

AN - SCOPUS:57149142767

VL - 199

SP - 596

EP - 609

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 6

ER -